Clinical trial · Interventional
Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis
A Single-Center, Two-Arm, Prospective Clinical Study Evaluating the Efficacy and Safety of a Topical Periplaneta Americana-Derived Regenerative Solution (Meilian Fuxin Liquid) for the Treatment of Radiation Dermatitis
NCT07353671CI-TRIAL-00106427recruitingPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the efficacy and safety of topical Periplaneta americana-derived Meilian Fuxin Solution for the prevention of radiation dermatitis in patients undergoing radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Radiation-induced Dermatitis | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiotherapy | Radiation | — | UNRESOLVED |
| Topical application of Periplaneta americana-derived Meilian Fuxin Solution | Drug | — | UNRESOLVED |
| Topical application of placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Meilian Fuxin Solution
- description
- Topical application of Periplaneta americana-derived Meilian Fuxin Solution
- interventionNames
- Drug: Topical application of Periplaneta americana-derived Meilian Fuxin Solution
- Radiation: Radiotherapy
- type
- PLACEBO_COMPARATOR
- label
- Control group
- description
- Topical application of placebo
- interventionNames
- Other: Topical application of placebo
- Radiation: Radiotherapy
Primary outcomes (1)
- measure
- Incidence of Grade 2 or Higher Acute Radiation Dermatitis (RTOG Criteria)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age and Gender: Patients aged 18 to 80 years (inclusive of boundary values), regardless of gender. 2. Diagnosis and Treatment: Patients with head and neck cancer (including nasopharyngeal carcinoma) who have been confirmed by histopathology and require radical radiotherapy or postoperative adjuvant radiotherapy. 3. Performance Status: Patients with an ECOG Performance Status score of 0 to 2. 4. Consent: Patients who voluntarily agree to participate in this study and sign the informed consent form. Exclusion Criteria: 1. Prior Radiotherapy: Patients with a history of prior radiotherapy to the target area. 2. Baseline Skin Condition: Baseline skin condition in the treatment area that may interfere with efficacy assessment (e.g., presence of open wounds, infection, rash, psoriasis, etc.). 3. Systemic Diseases: Presence of connective tissue diseases or other systemic dermatoses. 4. Known Allergies: Known allergy to any component of the investigational product (Meilian Fuxin Solution). 5. Prior Clinical Research: Participation in other interventional clinical studies within the past 3 months and use of any investigational drugs or devices. 6. Investigator Discretion: Subjects judged by the investigator to be unsuitable for participation in this clinical study.
References
Publications (0)
Data not yet available
No reference posted for this study.